

Assessed for eligibility (n = 86)
Excluded (n = 26)
Not meeting inclusion criteria (n = 15)
Declined to participate (n= 11)
Other reasons (n= 0)
Randomized (n = 60)
Sodium benzoate (n = 30)
Placebo (n = 30)
3.3% discontinued (n = 1)
0% adverse events (n = 0)
3.6% non-adherence to protocol (n =1)
0% unsatisfactory therapeutic effect (n = 0)
0% physical illnessed (n = 0)
16.7% discontinued (n =5)
3.6% adverse events (n =1)
0% non-adherence to protocol (n = 0)
7.1% unsatisfactory therapeutic effect (n = 2)
7.1% physical illnessed (n = 2)
100% completed at least one follow-up (n = 30)
100% completed at least one follow-up (n = 30)
96.7% completed the trial (n = 29)
83.3% completed the trial (n = 25)

FIG. 1